🔗 Share this article

As the US continues making sweeping revisions to its vaccination recommendations, one figure has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by questioning COVID-19 shots throughout the global health crisis and has zeroed in on possible fatalities after COVID-19 vaccination in her brief tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Vaccine Program

Public health authorities planned to reveal sweeping changes to the childhood vaccine schedule recently, synchronizing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US at odds with a large portion of the international standard with little proof for improved outcomes. The announcement has been pushed back until the next year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to present at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to head the office this calendar year.

A New Direction at the Regulatory Body

The acting appointment might represent a strengthened alliance between the drug and biologics branches as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it points to a increased emphasis upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for halting certain pediatric shot schedules in the US so as to align more like the Danish model, a nation with universal health coverage and a population about the size of the state of Wisconsin.

In her initial public appearances, she has kept her attention on vaccines – traditionally the domain of Dr. Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Doubts Over Background

The appointee has no obvious background in pharmaceutical research, regulation or administrative roles, which has been typical for previous leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She appears not to have the necessary background” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a major agency. She is not an expert in pharmaceutical oversight.”

Past commissioners of the center would “understand regulatory frameworks and the research of medication creation”, said Dr. Janet Woodcock. “Frankly, she doesn’t have the sort of resume that former directors who led CBER have had.”

CDER has an vast workload at the agency, the former commissioner pointed out.

“The public just pays attention on the new drug program, but the generic drug division clears thousands of generic medications. There’s a biologic copycat branch, over-the-counter program and more, and every single one must be managed,” Woodcock explained. “The area you overlook, that is the part that I always told people is going to cause problems.”

There is also, a significant leadership component to the job, which oversees more than 5,000 personnel. “It is a enormous leadership role, if you do it right,” she said.

Agency Reaction and Contentious Initiatives

When asked about inquiries about Dr. Høeg's fitness for the role and whether this appointment indicates increased cooperation among agency officials on immunizations, a spokesperson said that the “questions are based on incorrect assumptions”.

“Her experience is consistent with the functions of her role,” the representative said, pointing to the period Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg takes over the agency head's new priority voucher program, a contentious expedited medication authorization process that reportedly concerned her former heads. “How are these therapies being chosen for this fast-track system? Who takes the calls?” Dr. Howard questioned. “There’s a lot of secrecy occurring at the FDA right now.”

In general, he remarked, “the agency looks to be trending towards more relaxed rules of all drugs, with the exception of shots.”

Public Track Record on Vaccines

With vaccines, Dr. Høeg has a clearer, if concerning, track record, some experts have noted. She released a analysis using unverified volunteer-provided data to determine the rate of myocarditis after COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are riskier than they are.

Included in her “wish list” for the new administration included altering regulations for recently developed shots and halting “optional” immunizations, she said after the election on a audio program. At the FDA, Høeg has according to sources floated the idea of excluding teenage boys from getting COVID-19 vaccinations.

“She’s an complete dogmatist who commences with her preconceived notions and tailors the evidence to accommodate the data in a extremely misleading, untruthful way,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|